CL2015002488A1 - Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen - Google Patents

Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen

Info

Publication number
CL2015002488A1
CL2015002488A1 CL2015002488A CL2015002488A CL2015002488A1 CL 2015002488 A1 CL2015002488 A1 CL 2015002488A1 CL 2015002488 A CL2015002488 A CL 2015002488A CL 2015002488 A CL2015002488 A CL 2015002488A CL 2015002488 A1 CL2015002488 A1 CL 2015002488A1
Authority
CL
Chile
Prior art keywords
salt
preparation
pharmaceutical compositions
abexinostat
novel
Prior art date
Application number
CL2015002488A
Other languages
English (en)
Inventor
Anne Pimont-Garro
Philippe Letellier
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of CL2015002488A1 publication Critical patent/CL2015002488A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Abstract

SAL DE ABEXINOSTATO; FORMA CRISTALINA RELACIONADA; MÉTODO DE PREPARACIÓN DE ESTA Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN.
CL2015002488A 2013-03-04 2015-09-04 Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen CL2015002488A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CL2015002488A1 true CL2015002488A1 (es) 2016-03-11

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002488A CL2015002488A1 (es) 2013-03-04 2015-09-04 Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen

Country Status (39)

Country Link
US (3) US9115108B2 (es)
EP (2) EP3252044A1 (es)
JP (2) JP6449177B2 (es)
CN (2) CN105263917B (es)
AR (1) AR094935A1 (es)
AU (2) AU2014224456B2 (es)
BR (1) BR112015021443A2 (es)
CA (1) CA2903369C (es)
CL (1) CL2015002488A1 (es)
CR (1) CR20150456A (es)
CY (1) CY1119147T1 (es)
DK (1) DK2964622T3 (es)
DO (1) DOP2015000215A (es)
EA (2) EA039113B1 (es)
ES (1) ES2632471T3 (es)
FR (1) FR3002733B1 (es)
GE (1) GEP201706760B (es)
HK (1) HK1220965A1 (es)
HR (1) HRP20171041T1 (es)
HU (1) HUE035299T2 (es)
IL (1) IL241038B (es)
JO (1) JO3402B1 (es)
LT (1) LT2964622T (es)
MA (1) MA38423B1 (es)
ME (1) ME02814B (es)
MX (1) MX355436B (es)
MY (1) MY192027A (es)
NI (1) NI201500122A (es)
PE (1) PE20151591A1 (es)
PL (1) PL2964622T3 (es)
PT (1) PT2964622T (es)
RS (1) RS56224B1 (es)
SG (1) SG11201506952YA (es)
SI (1) SI2964622T1 (es)
TN (1) TN2015000367A1 (es)
TW (1) TWI506023B (es)
UA (1) UA118550C2 (es)
UY (1) UY35356A (es)
WO (1) WO2014135776A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CA2888960C (en) 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
KR20170043648A (ko) 2014-09-03 2017-04-21 파마싸이클릭스 엘엘씨 3-[(디메틸아미노)메틸]-n-｛2-[4-(히드록시카르바모일)페녹시]에틸｝-1-벤조푸란-2-카르복사미드의 신규 염, 관련 결정형, 이의 제조 방법 및 이를 함유하는 약학 조성물
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CA2775229C (en) * 2009-09-24 2014-07-29 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
DK2964622T3 (en) 2017-07-31
UY35356A (es) 2014-09-30
CN105263917B (zh) 2018-11-20
AU2018202881B2 (en) 2020-02-27
US20140249215A1 (en) 2014-09-04
HUE035299T2 (en) 2018-05-02
IL241038A0 (en) 2015-11-30
ME02814B (me) 2018-01-20
MA38423B1 (fr) 2017-10-31
CA2903369C (en) 2021-06-08
AU2014224456A1 (en) 2015-10-08
PT2964622T (pt) 2017-07-13
RS56224B1 (sr) 2017-11-30
EA201591530A1 (ru) 2016-01-29
JP2016510735A (ja) 2016-04-11
EA030689B1 (ru) 2018-09-28
SI2964622T1 (sl) 2017-10-30
JP6720280B2 (ja) 2020-07-08
TWI506023B (zh) 2015-11-01
FR3002733B1 (fr) 2015-08-14
IL241038B (en) 2019-09-26
EP2964622B1 (fr) 2017-04-19
CA2903369A1 (en) 2014-09-12
SG11201506952YA (en) 2015-10-29
US20150315167A1 (en) 2015-11-05
AU2014224456A8 (en) 2015-10-22
MX355436B (es) 2018-04-18
HRP20171041T1 (hr) 2017-10-06
CR20150456A (es) 2015-10-21
NZ712380A (en) 2020-10-30
MA38423A1 (fr) 2017-02-28
AR094935A1 (es) 2015-09-09
JP6449177B2 (ja) 2019-01-09
NI201500122A (es) 2018-10-18
DOP2015000215A (es) 2015-09-30
EP3252044A1 (fr) 2017-12-06
JP2019069955A (ja) 2019-05-09
MX2015011566A (es) 2016-06-24
PL2964622T3 (pl) 2017-10-31
CN109734690B (zh) 2023-08-11
BR112015021443A2 (pt) 2017-07-18
TN2015000367A1 (fr) 2017-01-03
US20170313671A1 (en) 2017-11-02
GEP201706760B (en) 2017-10-25
WO2014135776A1 (fr) 2014-09-12
PE20151591A1 (es) 2015-11-06
LT2964622T (lt) 2017-08-10
AU2014224456B2 (en) 2018-01-25
EP2964622A1 (fr) 2016-01-13
EA039113B1 (ru) 2021-12-06
UA118550C2 (uk) 2019-02-11
EA201891023A1 (ru) 2019-03-29
US10150748B2 (en) 2018-12-11
CN109734690A (zh) 2019-05-10
HK1220965A1 (zh) 2017-05-19
FR3002733A1 (fr) 2014-09-05
CN105263917A (zh) 2016-01-20
ES2632471T3 (es) 2017-09-13
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
CY1119147T1 (el) 2018-02-14
AU2018202881A1 (en) 2018-05-17
JO3402B1 (ar) 2019-10-20
MY192027A (en) 2022-07-23

Similar Documents

Publication Publication Date Title
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CL2016001871A1 (es) Anticuerpos humanos para pd-1
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
DK2970283T3 (da) Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201591137A1 (ru) Ингибиторы mk2 и их применения
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
BR112015021003A2 (pt) composições e métodos para a produção biológica de isopreno.
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR104591A1 (es) Piroglutamato de vortioxetina
MX2017000526A (es) Formulaciones de anticuerpos cristalinos.